Dr. Jeffrey L. Cummings

Research Professor, School of Integrated Health Sciences
Expertise: Neuroscience, neurodegenerative diseases, Alzheimer’s Disease, drug development, clinical trials, neurotherapeutics

Biography

Jeffrey L. Cummings, MD, ScD, joined the UNLV School of Integrated Health Sciences in 2019 as research professor within the department of brain health. Dr. Cummings is the Joy Chambers-Grundy Professor of Brain Science, an endowed professorship. He is the Director of the Chambers-Grundy Center for Transformative Neuroscience, a center devoted to using the tools of neuroscience and neurologic drug development to transform people’s lives.

Prior to UNLV, Dr. Cummings served as founding director of the Cleveland Clinic Lou Ruvo Center for Brain Health in Las Vegas, and as director of the Mary S. Easton Center for Alzheimer’s Disease Research, and director of the Deane F. Johnson Center for Neurotherapeutics, both at UCLA.

A world-renowned Alzheimer’s researcher and leader of clinical trials, Dr. Cummings has been recognized for his scientific and leadership contributions with the American Geriatrics Society’s Henderson Award (2006), the national Alzheimer’s Association’s Ronald and Nancy Reagan Research Award (2008), and the American Association of Geriatric Psychiatry’s Distinguished Scientist Award (2010). 

Dr. Cummings’ interests embrace clinical trials, developing new therapies for brain diseases, and the interface of neuroscience and society. Dr. Cummings has published nearly 800 articles and 44 books devoted to neuroscience, Alzheimer’s disease, and clinical trials.

Dr. Cummings received the Society for Behavioral and Cognitive Neurology’s Lifetime Achievement Award (2017), the International Society of CNS Drug Development’s Leadership and Achievement Award and the national Alzheimer’s Association’s Bengt Winblad Lifetime Achievement Award (2018).

Additionally, he was featured in Gentleman’s Quarterly (June 2009) as a “Rock Star of Science. ™” In addition to his work at UNLV, Dr. Cummings is professor of medicine (Neurology) at Cleveland Clinic Lerner College of Medicine at Case Western Reserve University, and he is principal investigator/director of the National Institute of General Medical Sciences-funded Center for Neurodegeneration and Translational Neuroscience.

Education

  • Sc.D., Science, University of Wyoming
  • Neurology fellowship, Boston University School of Medicine
  • Neuropathology/Neuropsychiatry fellowship, National Hospital for Nervous Diseases, London
  • M.D., Medicine, University of Washington
  • B.S., Zoology/Philosophy, University of Wyoming

Search For Other Experts On

health & medicine, science & technology

Dr. Jeffrey L. Cummings In The News

Business Insider
July 30, 2020
Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).
PRNewswire
July 29, 2020
Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism. Data linking the microbiome to Alzheimer's disease and GV-971 targeting the brain-gut axis launched by Shanghai Green Valley Pharmaceuticals were presented at the 34th Alzheimer's Association International Conference (AAIC).
Yahoo!
July 29, 2020
Alzheimer's disease has been an unsolved puzzle for scientists since the first patient was found over 100 years ago. Different theories like cholinergic hypothesis, amyloid cascade hypothesis, and tau protein hypothesis have made progress in research but failed to bring new therapies to patients. In recent years scientists started to focus on the brain-gut axis, with its breakthrough in the fields of Parkinson's disease, depression and autism.
Neurology Live
July 22, 2020
A systematic review of Alzheimer disease (AD) treatments currently in development demonstrate the progressive emphasis on nonamyloid targets, including candidate treatments addressing for inflammation, synapse and neuronal protection, vascular factors, neurogenesis, and epigenetic interventions.

Articles Featuring Dr. Jeffrey L. Cummings

A UNLV banner on campus.
Campus NewsJuly 2, 2020
A collection of news stories featuring the people and programs of UNLV.
artist rendering of brain
Campus NewsJune 15, 2020
The Chambers-Grundy Center for Transformative Neuroscience will advance research and the science of treatment for Alzheimer’s and other neurological disorders.
UNLV professor Matthew Lachniet works in his lab on campus.
PeopleDecember 27, 2019
A collection of stories highlighting UNLV faculty and students who made the news in 2019.
football players look up at fireworks display
Campus NewsDecember 2, 2019
A collection of local, national, and international news stories highlighting the people and programs of UNLV.